After decades of excruciating pain, a breakthrough sickle cell disease treatment made all the difference for one patient.

CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.

A groundbreaking new medical dataset is poised to revolutionize health care in Africa by improving chatbots' understanding of ...

An expert discusses how integrating newer NMIBC therapies faces operational barriers including administration logistics, staff training and formulary restrictions, while solutions require better ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Vertex Pharmaceuticals ...

The gene editing market represents one of the most transformative sectors in modern biotechnology, fundamentally reshaping how we approach genetic diseases, agricultural development, and therapeutic ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

To mark the NHS’ 75 th anniversary this year, NHS England partnered with the London College of Communication (LCC), part of the University of the Arts London, to provide students with real-life ...

The 2025 EHA Congress Awards honoured outstanding contributions across clinical care, research, education, and advocacy in ...

SINGLE clinical trial endpoints often fall short in capturing the full scope of patient experience, particularly in complex ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the appointment of Jay Backstrom ...

The mission aims to eliminate sickle cell anaemia by 2047 through universal screening and targeted tribal interventions.